Renal bone disease in patients on hemodialysis: an observational study focusing on the variation of calcium metabolism

Wajeeha Elahi, Ameen Zubair Syed, Bilal Jamil, Shahid Kamran, Raheela Adil, Nazia Qamar, Madiha Ariff, Adnan Anwar


Background: The aim of this study was to determine the disturbances in the levels of mineral in the body due to hemodialysis at different levels of parathormone levels and to assess its association with the calcium levels.

Methods: Study was a cross sectional for the period of 6 months taking ethical approval. Total 255 cases were registered in this study after taking their informed consent. The cases were divided into three groups according to PTH level. Group 1 has 87 subjects with PTH level <250, group 2 has 102 subjects with PTH level 250-650 and group 3 has 66 cases with PTH level >650. The cases were taking hemodialysis for greater than 6 months and have the ages more than 18 years were included in this study. The demographic data includes age, sex dialysis related data like duration of hemodialysis, levels of calcium, phosphorus, albumin, PTH, ALP were observed.

Results: Hemodialysis duration were recorded in respective three groups as 7.28±5.71, 6.26±5.56 and 6.15±4.30 days respectively  (P=0.319). Calcium was found in group 1, 8.70±0.81, in group 2, 8.39±0.89 and in group 3, 8.76±0.82 (P=0.01). PTH level in three respective group were recorded to be 123.46±74.15, 418.47±115.49 and 1314.67±1188.63 (P <0.001).

Conclusions: Present study showed that significant difference was found in mineral levels in patients on hemodialysis with PTH level as well as with alkaline phosphatase level. Nevertheless, no significant difference was found with duration of dialysis and with parameter of albumin.


Calcium metabolism, Cross sectional study, Developing country, Dialysis duration, Mineral levels

Full Text:



Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl. 2015;5 (1):2-7.

Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10 (1):98-109.

Fukagawa M, Komaba H. Chronic kidney disease-mineral and bone disorder in Asia. Kidney Dis. 2017;3 (1):1-7.

Movahed SM, Mousavi SS, Faramarzi M. Secondary hyperparathyroidism among end-stage renal disease patients in Beharlou Hospital, Tehran Province, Iran. J Parathyroid Dis. 2018;6 (2):65-9

Jovanovich A, Chonchol M. Phosphorus and kidney disease: mechanisms for perturbed phosphorus homeostasis in chronic kidney disease. Clin Aspects Nat Added Phosphorus Foods. 2017:187-99.

Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2010;26 (6):1948-55.

Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74 (3):276-88.

Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71 (1):31-8.

Chertow GM, Plone M, Dillon MA, Burke SK, Slatopolsky E. Hyperparathyroidism and dialysis vintage. Clin Nephrol. 2000;54 (4):295-300.

Kim SM, Long J, Montez-Rath ME, Leonard MB, Norton JA, Chertow GM. Rates and outcomes of parathyroidectomy for secondary hyper-parathyroidism in the United States. Clin J Am Soc Nephrol. 2016;11 (7):1260-7.

Lacson E, Wang W, Hakim RM, Teng M, Lazarus JM. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis. 2009;53 (1):79-90.

Martín FJL, Camblor MP, Dionisi MP, Floege J, Ketteler M, London G, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30 (9):1542-51.

Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305 (11):1119-27.

Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2015;87 (3):502-8.

Moorthi RN, Moe SM. CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis. 2011;58 (6):1022-36.

Hocher B, Pasch A. Hope for CKD-MBD Patients: new diagnostic approaches for better treatment of CKD-MBD. Kidney Dis. 2017;3(1):8-14.

Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, et al. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol. 2015;26 (10):2328-39.

Marks J, Debnam ES, Unwin RJ. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiology-Renal Physiol. 2010;299 (2):285-96.

Ghonemy TA, Allam HM, Elokely AM, Kadry YA, Omar HM. Chronic pain in hemodialysis patients: Role of bone mineral metabolism. Alexandria J Med. 2016;52(4):337-42.

Wang WH, Chen LW, Lee CC, Sun CY, Shyu YC, Hsu HR et al. Association between Parathyroid Hormone, 25 (OH) Vitamin D, and Chronic Kidney Disease: A Population-Based Study. BioMed Res Int. 2017;34(2):1-9.

Soleymanian T, Nikzad N, Mahjoub A, Argani H, Saavaj S. Serum levels of intact parathyroid hormone, calcium, and phosphorus and risk of mortality in hemodialysis patients. Nephro-Urol Monthly. 2017;9(1):1-8

Omidvar B, Ghorbani A, Tamadon MR, Broujeni ZS, Bahadoram M, Dargahi, et al. Relationship of bone density with serum parathyroid hormone in hemodialysis patients; a single center study. J Parathyroid Dis. 2018;6(2):57-63.

Gomez AT, Kiberd BA, Royston JP, Alfaadhel T, Soroka SD, Hemmelgarn BR, et al. Comorbidity burden at dialysis initiation and mortality: a cohort study. Canadian J Kidney Health Dis. 2015;2 (1):34-42.

Zhang Y, Cotter DJ, Thamer M. The effect of dialysis chains on mortality among patients receiving hemodialysis. Health Services Res. 2011;46 (3):747-67.

Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis. 2012;12 (1):265-72.

Kong X, Zhang L, Chen N, Gu Y, Yu X, Liu W, et al. Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol. 2012;13:116-32.

Erdem E. Proton pump inhibitors use in hemodialysis patients and serum magnesium levels. Int J Clin Experiment Med. 2015;8(11):21689-93.

Wikström B. Itchy skin-a clinical problem for haemodialysis patients. Nephrol Dial Transplant. 2007;22(5):3-7.

Kesikburun B, Ekşioğlu E, Akdağ İ, Çakçı A. Low back pain in hemodialysis patients: Risk factors and its impact on health-related quality of life. Turk J Physical Med Rehabil. 2018;64(1):66-71.